Skip to search formSkip to main contentSkip to account menu

MDL 73,147EF

Known as: MDL-73,147 EF, MDL73,147EF, MDL-73147EF 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Dolasetrondolasetron mesylate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
Buspirone functionally discriminates tissues endowed with alpha1-adrenoceptor subtypes A, B, D and L.
Highly Cited
1994
Highly Cited
1994
Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin.
PURPOSE This dose-ranging trial of intravenous dolasetron mesylate (MDL73,147EF) was performed to determine its adverse and… 
1994
1994
Effects of 5-HT1A receptor ligands on a safety signal withdrawal procedure of conflict in the rat
1994
1994
Acute Antiemetic Efficacy and Safety of Dolasetron Mesylate, A 5‐HT3 Antagonist, in Cancer Patients Treated with Cisplatin
Dolasetron mesylate (MDL 73,147EF), a new serotonin receptor (5-HT3) antagonist was administered to 164 cancer patients naive or… 
1994
1994
A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapy.
BACKGROUND We conducted a phase I study with MDL 73,147EF, a new 5 hydroxytryptamine 3 (5-HT3) receptor antagonist, in 25… 
Review
1991
Review
1991
5-HT3 Receptor Antagonists
SummaryThe serotonin (5-hydroxytryptamine, 5-HT) antagonists, which bind at the type 3 receptor (5-HT3 receptor), have been… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)